A combination of MEK inhibitors and PDGFR/RAF-dimer inhibitors may overcome this resistance, offering a novel targeted therapeutic approach for NF1-deficient MPNST patients (195). Here, PDGFRB is linked to malignant peripheral nerve sheath tumor.